文献速递肝病消化道肿瘤与早癌

CHK2过表达及在有丝分裂结构中的错误定位增强染色体不稳定性并促进肝细胞癌进展

CHK2 overexpression and mislocalisation within mitotic structures enhances chromosomal instability and hepatocellular carcinoma progression.
PubMed 文献 · Gut · 2017-03-30

本研究在二乙基亚硝胺诱导的肝细胞癌动物模型及两个独立人类肝细胞癌标本队列中评估DNA损伤应答蛋白检查点激酶2(Chk2)的表达,并通过HCT116、Huh7及hTERT永生化人肝细胞进行功能实验。研究发现有丝分裂错误导致滞后染色体/DNA损伤并激活Chk2,Chk2过表达/磷酸化及在有丝分裂纺锤体中的错误定位促进滞后染色体产生,敲低Chk2可逆转滞后染色体和有丝分裂活性。两个队列显示部分肝细胞癌患者存在强烈的Chk2细胞质向细胞核转位,作者提出Chk2可作为检测染色体不稳定性的候选生物标志物。

要点

  • 肝细胞癌发生过程中的有丝分裂错误引起滞后染色体/DNA损伤并激活Chk2。
  • Chk2过表达/磷酸化及在纺锤体错误定位促进滞后染色体,敲低Chk2可逆转。
  • 两个独立队列显示部分肝细胞癌患者存在Chk2细胞质向细胞核转位。

核心结论

  • 本研究揭示了Chk2参与肝细胞癌进展的新机制,作者提出Chk2可作为检测肝细胞癌染色体不稳定性的候选生物标志物,为患者的临床/治疗管理提供有价值的支持。

研究设计与样本

  • 在二乙基亚硝胺诱导的、以DNA损伤和有丝分裂错误升高为特征的肝细胞癌动物模型中评估Chk2表达。
  • 在两个独立的人类肝细胞癌标本队列中检测Chk2。
  • 利用HCT116、Huh7及hTERT基因永生化的人肝细胞(HuS)进行功能获得与缺失、诱变、核型分析和免疫荧光/活细胞成像实验以评估Chk2的功能作用。

主要发现

  • 肝细胞癌肿瘤发生过程中的有丝分裂错误导致滞后染色体/DNA损伤并激活Chk2。
  • Chk2的过表达/磷酸化及在有丝分裂纺锤体内的错误定位促进滞后染色体产生。
  • 敲低Chk2可逆转滞后染色体和有丝分裂活性。
  • 上调的Chk2通过与Aurora B激酶相互作用维持有丝分裂活性以促进染色体凝集和胞质分裂。
  • Chk2的叉头相关结构域是Chk2错误定位至有丝分裂结构所必需的。

临床怎么用

  • 作者提出Chk2可作为检测肝细胞癌染色体不稳定性的候选生物标志物,为患者的临床/治疗管理提供有价值的支持。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Chromosomal instability (CIN) is the most common form of genomic instability, which promotes hepatocellular carcinoma (HCC) progression by enhancing tumour heterogeneity, drug resistance and immunity escape. CIN per se is an important factor of DNA damage, sustaining structural chromosome abnormalities but the underlying mechanisms are unknown. DESIGN: DNA damage response protein checkpoint kinase 2 (Chk2) expression was evaluated in an animal model of diethylnitrosamine-induced HCC characterised by DNA damage and elevated mitotic errors. Chk2 was also determined in two discrete cohorts of human HCC specimens. To assess the functional role of Chk2, gain on and loss-of-function, mutagenesis, karyotyping and immunofluorescence/live imaging were performed by using HCT116, Huh7 and human hepatocytes immortalised with hTERT gene (HuS). RESULTS: We demonstrate that mitotic errors during HCC tumorigenesis cause lagging chromosomes/DNA damage and activation of Chk2. Overexpression/phosphorylation and mislocalisation within the mitotic spindle of Chk2 contributes to induce lagging chromosomes. Lagging chromosomes and mitotic activity are reversed by knockdown of Chk2. Furthermore, upregulated Chk2 maintains mitotic activity interacting with Aurora B kinase for chromosome condensation and cytokinesis. The forkhead-associated domain of Chk2 is required for Chk2 mislocalisation to mitotic structures. In addition, retinoblastoma protein phosphorylation contributes to defective mitoses. A cohort and independent validation cohort show a strong cytoplasm to nuclear Chk2 translocation in a subset of patients with HCC. CONCLUSIONS: The study reveals a new mechanistic insight in the coinvolvement of Chk2 in HCC progression. These findings propose Chk2 as a putative biomarker to detect CIN in HCC providing a valuable support for clinical/therapeutical management of patients.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Carloni V, Lulli M, Madiai S, et al. CHK2 overexpression and mislocalisation within mitotic structures enhances chromosomal instability and hepatocellular carcinoma progression. Gut. 2017. PMID: 28360097. doi:10.1136/gutjnl-2016-313114

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。